Literature DB >> 17551137

Cisplatin versus carboplatin for patients with metastatic non-small-cell lung cancer--an old rivalry renewed.

Christopher G Azzoli, Mark G Kris, David G Pfister.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17551137     DOI： 10.1093/jnci/djk222

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  10 in total

Review 1.  Direct Activation of Bax Protein for Cancer Therapy.

Authors:  Zhiqing Liu; Ye Ding; Na Ye; Christopher Wild; Haiying Chen; Jia Zhou
Journal:  Med Res Rev       Date:  2015-09-23       Impact factor: 12.944

2.  Temporal patterns of care and outcomes of non-small cell lung cancer patients in the United States diagnosed in 1996, 2005, and 2010.

Authors:  Filip Kaniski; Lindsey Enewold; Anish Thomas; Shakuntala Malik; Jennifer L Stevens; Linda C Harlan
Journal:  Lung Cancer       Date:  2016-11-29       Impact factor: 5.705

3.  Comparison of cisplatin- and carboplatin-based third-generation chemotherapy in 1,014 Chinese patients with advanced non-small-cell lung cancer.

Authors:  Jie Luo; Shiang J Leaw; Ying Xu; Di Zheng
Journal:  Med Oncol       Date:  2010-07-27       Impact factor: 3.064

4.  Impact of renal function on treatment options and outcomes in advanced non-small cell lung cancer.

Authors:  Bercin Kutluk Cenik; Han Sun; David E Gerber
Journal:  Lung Cancer       Date:  2013-03-15       Impact factor: 5.705

5.  Activation of the proapoptotic Bcl-2 protein Bax by a small molecule induces tumor cell apoptosis.

Authors:  Guoping Zhao; Yanglong Zhu; Colins O Eno; Yanlong Liu; Lynn Deleeuw; Joseph A Burlison; Jonathan B Chaires; John O Trent; Chi Li
Journal:  Mol Cell Biol       Date:  2014-01-13       Impact factor: 4.272

6.  Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small-cell lung cancer.

Authors:  G P Stathopoulos; D Antoniou; J Dimitroulis; J Stathopoulos; K Marosis; P Michalopoulou
Journal:  Cancer Chemother Pharmacol       Date:  2011-02-08       Impact factor: 3.333

7.  Nedaplatin or oxaliplatin combined with paclitaxel and docetaxel as first-line treatment for patients with advanced non-small cell lung cancer.

Authors:  Keqian Zhang; Hong Qin; Feng Pan; Enqiang Liu; Houjie Liang; Zhihua Ruan
Journal:  Med Sci Monit       Date:  2014-12-30

Review 8.  Folic Acid Antimetabolites (Antifolates): A Brief Review on Synthetic Strategies and Application Opportunities.

Authors:  Igor S Kovalev; Grigory V Zyryanov; Sougata Santra; Adinath Majee; Mikhail V Varaksin; Valery N Charushin
Journal:  Molecules       Date:  2022-09-22       Impact factor: 4.927

9.  Validity of new methods to evaluate renal function in cancer patients treated with cisplatin.

Authors:  Yohei Funakoshi; Yutaka Fujiwara; Naomi Kiyota; Toru Mukohara; Takanobu Shimada; Masanori Toyoda; Yoshinori Imamura; Naoko Chayahara; Hideo Tomioka; Michio Umezu; Naoki Otsuki; Ken-ichi Nibu; Hironobu Minami
Journal:  Cancer Chemother Pharmacol       Date:  2016-01-20       Impact factor: 3.333

10.  Sequential Treatment with an Immune Checkpoint Inhibitor Followed by a Small-Molecule Targeted Agent Increases Drug-Induced Pneumonitis.

Authors:  Jongheon Jung; Hyae Young Kim; Dong-Gil Kim; Seog Yun Park; A Ra Ko; Ji-Youn Han; Heung Tae Kim; Jin Soo Lee; Youngjoo Lee
Journal:  Cancer Res Treat       Date:  2020-08-06       Impact factor: 4.679
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.